Quick Answer
Kyverna Therapeutics, Inc. reported Earnings Per Share Diluted of $3.64 (loss) per share for the year ending 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -9.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Kyverna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $12.10 (loss) per share | Q2 2023: $20.86 (loss) per share | Q3 2023: $23.27 (loss) per share | Q1 2024: $1.12 (loss) per share | Q2 2024: $0.67 (loss) per share | Q3 2024: $0.80 (loss) per share | Q1 2025: $1.03 (loss) per share | Q2 2025: $0.97 (loss) per share | Q3 2025: $0.85 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), Kyverna Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 95.9%.
- Historical annual values: Fiscal year 2025: $3.64 (loss) per share | Fiscal year 2024: $3.33 (loss) per share | Fiscal year 2023: $89.61 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: